Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | SRC positive |
| Therapy | Bosutinib + Gemcitabine |
| Indication/Tumor Type | biliary tract cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| SRC positive | biliary tract cancer | sensitive | Bosutinib + Gemcitabine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Bosulif (bosutinib) and Gemzar (gemcitabine) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758). | 27196758 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27196758) | Src as a Therapeutic Target in Biliary Tract Cancer. | Full reference... |